Indications
Positive diagnosis of relapsing ovarian adenocarcinoma when serum CA 125 is increased without positive results of ultrasound or computerised tomography scan.
Composition
- Active substance
- igovomab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Indimacis 125
- Active substance
- igovomab
- ATC code
- V09IB03
- Group
- Various
- Therapeutic area
- Radionuclide Imaging, Ovarian Neoplasms
- Marketing authorisation holder
- CIS bio international
- Status
- Withdrawn
- EU authorisation
- 4 Oct 1996